Oncotelic Therapeutics, Inc.
Income Statement
| Line Item | FY2023 | FY2020 | FY2013 | FY2012 |
|---|---|---|---|---|
| Revenue | $70.0K | $1.7M | $95.0K | $156.0K |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $61.1K | $4.3M | $3.6M | $3.5M |
| SG&A Expense | $573.7K | $5.0M | $4.7M | $4.7M |
| Operating Income | $-6.6M | $-7.6M | $-8.3M | $-8.1M |
| Operating Margin | -9,497.2% | -435.7% | -8,715.8% | -5,174.4% |
| Interest Expense | $1.0M | $2.0M | — | — |
| Pretax Income | — | — | — | — |
| Income Tax Expense | — | — | $0 | — |
| Net Income | $-7.9M | $-9.5M | $-8.3M | $-8.1M |
| Net Margin | -11,290.1% | -545.9% | -8,712.6% | -5,178.8% |
| EPS (Basic) | $-0.02 | $-0.04 | $-1.56 | $-1.83 |
| EPS (Diluted) | $-0.02 | $-0.04 | $-1.56 | $-1.83 |
| Shares Outstanding (Basic) | 384.1M | 264.3M | 16.8M | 5.2M |
| Shares Outstanding (Diluted) | 396.2M | 264.3M | 16.8M | 5.2M |
| Dividends Per Share | — | — | — | — |